Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:Q06643 (non-Hodgkin's lymphoma)
 11,307 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

From 1969 to 1978, 11 patients with non-Hodgkin's lymphoma presenting as thyroid enlargement were evaluated and treated in the Division of Radiation Therapy at Stanford University Hospital. All patients were staged with lymphangiogram and bone marrow biopsy. Eight patients had Stage I-II disease and three patients had Stage III-IV disease. The histologic pattern of the biopsies was diffuse in nine cases, and eight cases were classified as histiocytic lymphoma. All eight patients with Stage I or II disease were treated with irradiation. There is an 83.3% survival at three years and a 75% relapse-free survival at two years. No instance of local recurrence was observed in this group of patients. The three patients with Stage III or IV disease were treated by either irradiation or chemotherapy. Two relapsed within one year and died with disease; the third remained free of disease for nine years before relapse and died with disease six months later. High dose regional irradiation is the recommended treatment for patients with Stage I-II lymphoma of the thyroid.
 ...
PMID:Non-Hodgkin's lymphoma presenting as thyroid enlargement. 703 Apr 69

Twenty-two cases of primary gastric non-Hodgkin's lymphoma, which occurred over a 20-year period, were reviewed. Eighteen tumors were studied using an immunoperoxidase method, and the presence of intracytoplasmic monoclonal immunoglobulin (Ig) in nine (50%) suggested a B-cell origin. Four tumors (22%) contained intracytoplasmic muramidase (lysozyme), suggesting a true histiocytic origin. Five tumors (28%) did not contain immunoglobulin or muramidase. The muramidase-positive "true histiocytic lymphoma" could not be differentiated from histiocytic lymphoma of lymphocytic origin using light microscopic examination alone. The patients with B-cell lymphoma survived significantly longer than patients in the other two groups. The differentiation between true histiocytic lymphoma and other conditions is discussed.
 ...
PMID:A combined morphologic and immunologic approach to the diagnosis of gastrointestinal lymphomas: I. Malignant lymphoma of the stomach (a clinicopathologic study of 22 cases). 703 47

Manitoba tumour registry data for patients with non-Hodgkin's lymphoma diagnosed between 1968 and 1977 inclusive who were given chemotherapy were reviewed. The Rappaport classification of these tumours enabled general pathologists in the province to distinguish three main prognostic groups. Combination chemotherapy improved survival significantly more than single-agent chemotherapy only for the patients with diffuse histiocytic lymphoma, not for those with diffuse poorly differentiated lymphocytic lymphoma or the more favourable histologic types of non-Hodgkin's lymphoma--diffuse well differentiated lymphocytic and nodular poorly differentiated lymphocytic. For the last two types, therefore, the more intensive chemotherapy is not justified.
 ...
PMID:Non-Hodgkin's lymphoma in Manitoba, 1968-77: the impact of chemotherapy. 704 60

The pretreatment concentrations of polyamines were determined in the 24-hr urine of 14 patients with widespread non-Hodgkin's lymphoma. In ten of 14 patients, the ratio of N1-acetylspermidine to N8-acetylspermidine was significantly higher than the mean for normal subjects. These results confirm our previous observations that the urinary excretion of N1-acetylspermidine is increased in some patients with lymphoma and suggest that the determination of urinary acetyl polyamines may be useful in conjunction with other procedures in the diagnosis of lymphoma. The ratio of N1-acetylspermidine to N8-acetylspermidine in the postchemotherapy 24-hr urine was 25 in one patient who had diffuse histiocytic lymphoma. This is the highest ratio ever reported. The patient responded well to chemotherapy, and rapid lysis of lymphoma lesion was observed. The potential utility of the rapid increase in the ratio of N1-acetylspermidine to N8-acetylspermidine as a criterion of tumor lysis is of interest and is currently under further investigation.
 ...
PMID:Urinary excretion of monoacetyl polyamines in patients with non-Hodgkin's lymphoma. 706 12

The VM*P combination chemotherapy was administered to 13 patients with advanced (Stage III and IV) non-Hodgkin's lymphoma refractory to previous multiagent chemotherapy including cyclophosphamide (EX) and/or adriamycin (ADM). 1) Complete response was obtained in two patients with diffuse histiocytic lymphoma and one patient with diffuse undifferentiated (Burkitt type) lymphoma, and a response rate was 46.2%. 2) Tumor regression in responders was recognized within one week after administration of VM*P, but the duration of response was only 7(2-17) weeks in median (range). 3) Positive correlation was not seen between responsibility and dose of vincristine or methotrexate (MTX), but complete responders were obtained with only over 30 mg/dose of MTX. 4) In spite of resistant cases against EX and/or ADM, complete responders were obtained with VM*P therapy. Clinically, it was shown that cross resistance was minimal among MTX, EX and ADM. 5) Major side effects of VM*P therapy were myelosuppression (75%), hepatotoxicity (46%), and severe infection (23%). Neurotoxicity and nephrotoxicity were rare.
 ...
PMID:[A preliminary study of vincristine, methotrexate, and prednisolone (VM*P) combination chemotherapy for advanced adult non-Hodgkin's lymphoma]. 718 75

Between January 1976 and December 1980, 16 patients with advanced Hodgkin's Disease and 70 patients with Stage III and Stage IV Non-Hodgkin's lymphoma were treated with combination chemotherapy, 12 patients with Hodgkin's disease were treated with nitrogen mustard, vinblastine, procarbazine (MVPP). 4 patients received MVPP. 4 patients received MOPP (O = vincristine). 69% of the patients showed disease remission. 25% of the patients achieved complete remission. 58 patients with advanced non-Hodgkin's lymphoma were treated with the quadruple drug combination of cyclophosphamide, vincristine, procarbazine and prednisolone (COPP). 21% of the patients with non-Hodgkin's lymphoma developed a frankly leukaemic transformation which complicated management. Response rate to COPP therapy was 44% for all patients. 43% of the patients showed no response to treatment. Of the patients who showed disease remission with COPP, 52% achieved a complete remission. Percentage survival at 2 years for all patients was 14% compared with 47% for patients with complete remission. Using the Rappaport classification for histological subtype in non-Hodgkin's lymphoma, 61% of diffused poorly differentiated lymphoma showed disease remission compared to 47% remission in diffused histiocytic lymphoma. Only 33% of lympho-blastic lymphoma responded to COPP. Patients with leukaemic transformation did not respond to COPP. 9 of 15 patients with a leukaemic phase showed partial remission with combination chemotherapy. Majority of patients on combination chemotherapy showed evidence of drugs toxicity both in the Hodgkin's group and the non-Hodgkin's group. Major drug toxicities were myelosuppression and neurotoxicity.
 ...
PMID:Chemotherapy of malignant lymphoma. 733 96

The activities of thymidine kinase (TK) isoenzyme 1 and 2 were examined in extracts of human benign or malignant lymphoid tissue and correlated with degrees of morphological differentiation. TK2 activity occurred in peripheral blood lymphocytes of normal individuals, patients with chronic lymphocytic leukemia, or solid lymphoid tissue, exhibiting either nonneoplastic histological findings or those of diffuse well-differentiated lymphocytic lymphoma. TK1 activity occurred in solid, non-Hodgkin's lymphoma tissue, exhibiting lesser degrees of cellular differentiation, or in peripheral blood lymphocytes of patients with clinical aggressive chronic lymphocytic leukemia or lymphosarcoma leukemia. In non-Hodgkin's lymphoma tissue, the range of TK1 activities correlated broadly with the Rappaport classification, with higher values occurring in tissue exhibiting changes of diffuse poorly differentiated lymphocytic lymphoma or diffuse histiocytic lymphoma.
 ...
PMID:Thymidine kinase isoenzymes in human malignant lymphoma. 744 15

Pulmonary parenchymal involvement and mediastinal lymphadenopathy are less common manifestations of non-Hodgkin's lymphoma as compared to Hodgkin's lymphoma. The pattern of pulmonary disease varies with histological type of non-Hodgkin's lymphoma. We are presenting an uncommon case of diffuse histiocytic lymphoma having miliary mottling who responded well to chemotherapy.
 ...
PMID:Miliary mottling in non-Hodgkins lymphoma. 803 22

Between August 1984 and September 1990, 13 children with non-Hodgkin's lymphoma (NHL) were treated with ALL high-risk protocol (5 with TCLSG 842 regimen and 8 with TPOG 882B protocol) at Taichung Veterans General Hospital. Diagnosis of NHL was confirmed by histology. Nine had lymphoblastic lymphoma, three had histiocytic lymphoma and one had small non-cleaved cell lymphoma, according to the Rappaport classification. After thorough clinical evaluation eight children were NHL stage IV; four were stage III; and one was stage II. All these children had received chemotherapy as acute lymphocytic leukemia (ALL) high-risk protocol for a total of three years, including central nervous system (CNS) prophylaxis. Of the 13 patients, 9 (69.2%) gained complete remission. Over-all survival rate was 46.2%, with a median interval of 36 months. The complete remission rate and survival rate for the nine children with lymphoblastic lymphoma was better at 77.7% & 66.6% respectively. Within the nonresponsive group, two failed to remit because of early withdrawal from the protocol; the other two patients were refractory to treatment. Relapse was noted in one patient. As to the side effects, neutropenic fever was the most common problem encountered (9 occurrences in 13 patients). Other major complications included severe mucositis, massive GI bleeding, intracranial thrombosis induced by l-asparaginase and tumor lysis syndrome. Childhood NHL is often of diffuse types in pathology, and most affected children have advanced diseases at diagnosis. Choosing an optimal treatment protocol is important for good treatment results.
 ...
PMID:Childhood non-Hodgkin's lymphoma--results of treatment with ALL high-risk protocol. 837 67

Monocytes and macrophages are closely related in origin, structure and function. True histiocytic lymphoma is a neoplasm of phagocytic histiocytes and is treated as non-Hodgkin's lymphoma. Tissue involvement with myeloid leukemia, including monocytic leukemia, is called extramedullary myeloid cell tumor or granulocytic sarcoma and treated with antileukemic chemotherapy. Differentiating true histiocytic lymphoma from tissue involvement with monocytic leukemia is a rather impossible task using available morphologic, cytochemical, immunocytochemical and molecular methods. The two entities need to be unified probably more appropriately as extramedullary myeloid cell tumor of monocytic origin, and should therefore be treated as such.
 ...
PMID:True histiocytic lymphoma: is it an entity? 918 Mar 4


<< Previous 1 2 3 4 5 6 7 8 9 Next >>